These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Ulcerative colitis after autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma. Koike K; Kohda K; Kuga T; Nakazawa O; Ando M; Takayanagi N; Matsunaga T; Sakamaki S; Niitsu Y Bone Marrow Transplant; 2001 Sep; 28(6):619-21. PubMed ID: 11607778 [TBL] [Abstract][Full Text] [Related]
3. Expression of a free gamma heavy chain in serum following autologous stem cell transplantation for IgG kappa multiple myeloma. Butch AW; Badros A; Desikan KR; Munshi NC Bone Marrow Transplant; 2001 Mar; 27(6):663-6. PubMed ID: 11319600 [TBL] [Abstract][Full Text] [Related]
4. Chimerism and T-cell receptor repertoire analysis after unrelated cord blood transplantation with a reduced-intensity conditioning regimen following autologous stem cell transplantation for multiple myeloma. Toubai T; Hirate D; Shono Y; Ota S; Ibata M; Mashiko S; Sugita J; Shigematsu A; Miura Y; Kato N; Umehara S; Kahata K; Tsutsumi Y; Iwao N; Toyoshima N; Tanaka J; Asaka M; Imamura M Int J Lab Hematol; 2008 Feb; 30(1):75-81. PubMed ID: 18190473 [TBL] [Abstract][Full Text] [Related]
5. [Development of Hodgkin's disease four years after autologous peripheral blood stem cell transplantation for multiple myeloma]. Fujii H; Iwai T; Ueda Y; Nakagawa H Rinsho Ketsueki; 2000 Dec; 41(12):1267-72. PubMed ID: 11201152 [TBL] [Abstract][Full Text] [Related]
6. A comparison of CD34+ cell selected and unselected autologous peripheral blood stem cell transplantation for multiple myeloma: a case controlled analysis. Gandhi M; Jestice H; Scott M; Bloxham D; Bass G; Craig J; Marcus R Bone Marrow Transplant; 1999 Aug; 24(4):369-75. PubMed ID: 10467325 [TBL] [Abstract][Full Text] [Related]
7. High dose chemotherapy followed by autologous haemopoietic stem cell transplant in multiple myeloma. Kumar L; Raju GM; Ganessan K; Shawgi S; Menon H; Wadhwa J; Sharma A; Singh R; Kochupillai V Natl Med J India; 2003; 16(1):16-21. PubMed ID: 12715951 [TBL] [Abstract][Full Text] [Related]
9. Modified conditioning regimen busulfan-cyclophosphamide followed by allogeneic stem cell transplantation in patients with multiple myeloma. Zhang XH; Huang XJ; Liu KY; Xu LP; Liu DH; Chen H; Chen YH; Wang JZ; Han W; Lu DP Chin Med J (Engl); 2007 Mar; 120(6):463-8. PubMed ID: 17439737 [TBL] [Abstract][Full Text] [Related]
10. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma. Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493 [TBL] [Abstract][Full Text] [Related]
11. Results of autologous and allogeneic hematopoietic cell transplant therapy for multiple myeloma. Arora M; McGlave PB; Burns LJ; Miller JS; Barke JN; Defor TE; Weisdorf DJ Bone Marrow Transplant; 2005 Jun; 35(12):1133-40. PubMed ID: 15834435 [TBL] [Abstract][Full Text] [Related]
13. Autologous stem cell transplantation in multiple myeloma after VAD and EDAP courses: a high incidence of oligoclonal serum Igs post transplantation. Hovenga S; de Wolf JT; Guikema JE; Klip H; Smit JW; Smit Sibinga CT; Bos NA; Vellenga E Bone Marrow Transplant; 2000 Apr; 25(7):723-8. PubMed ID: 10745257 [TBL] [Abstract][Full Text] [Related]
14. Refractory thrombocytopenia due to anti-PLA1 antibodies following autologous peripheral blood stem cell transplantation: case report and review of literature. Roy V; Verfaillie CM Bone Marrow Transplant; 1996 Jan; 17(1):115-7. PubMed ID: 8673043 [TBL] [Abstract][Full Text] [Related]
16. Oral mucositis and outcomes of autologous hematopoietic stem-cell transplantation following high-dose melphalan conditioning for multiple myeloma. Vera-Llonch M; Oster G; Ford CM; Lu J; Sonis S J Support Oncol; 2007 May; 5(5):231-5. PubMed ID: 17564153 [TBL] [Abstract][Full Text] [Related]
17. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma. Hiwase DK; Hiwase S; Bailey M; Bollard G; Schwarer AP Biol Blood Marrow Transplant; 2008 Jan; 14(1):116-24. PubMed ID: 18158968 [TBL] [Abstract][Full Text] [Related]
18. Autoimmunity following haematopoietic stem-cell transplantation. Daikeler T; Tyndall A Best Pract Res Clin Haematol; 2007 Jun; 20(2):349-60. PubMed ID: 17448966 [TBL] [Abstract][Full Text] [Related]
19. Induction therapy with vincristine, adriamycin, dexamethasone (VAD) and intermediate-dose melphalan (IDM) followed by autologous or allogeneic stem cell transplantation in newly diagnosed multiple myeloma. Lokhorst HM; Sonneveld P; Cornelissen JJ; Joosten P; van Marwijk Kooy M; Meinema J; Nieuwenhuis HK; van Oers MH; Richel DJ; Segeren CN; Veth G; Verdonck LF; Wijermans PW Bone Marrow Transplant; 1999 Feb; 23(4):317-22. PubMed ID: 10100574 [TBL] [Abstract][Full Text] [Related]
20. Secondary acute myeloid leukemia and myelodysplasia after autologous peripheral blood progenitor cell transplantation. Sevilla J; Rodríguez A; Hernández-Maraver D; de Bustos G; Aguado J; Ojeda E; Arrieta R; Hernández-Navarro F Ann Hematol; 2002 Jan; 81(1):11-5. PubMed ID: 11807629 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]